Toothpaste Giant's Bold Beauty Pivot

EPL Ltd, historically known for its dominance in toothpaste tubes, is undergoing a significant transformation to establish premium beauty packaging as its next major growth driver.

The company's strategic focus has shifted deliberately towards beauty, cosmetics, and pharmaceutical packaging over several years. This initiative is now clearly reflected in its financial performance, with the Beauty and Cosmetics segment experiencing a 23.6% growth during the June quarter.

This shift is more than a portfolio adjustment; beauty brands require customized designs and premium finishes, making packaging integral to the product experience. EPL aims to increase its market share in this segment from 8% to approximately 16% in the coming years.

Financially, the June quarter showed a 25.3% year-on-year revenue increase and a 15.2% rise in operating EBITDA. However, Profit After Tax (PAT) saw a slight decrease of 1.4%, attributed to an unusually low tax rate in the prior year.

Underlying EBITDA margins are reported at 19.6%, with management confident in their ability to manage commodity price inflation through pricing strategies. This marks the fifth consecutive quarter of double-digit underlying growth, signaling that recent investments are beginning to yield results.

The company's transformation is evident in its revenue mix, with Personal Care & Beyond now accounting for 54% of tube revenue, a substantial increase from 43% in FY19. EPL has invested in a dedicated Beauty and Cosmetics Centre of Excellence and specialized sales teams.

Despite this progress, Europe presents a challenge, with revenue up 20.2% but profitability declining due to restructuring costs and operational inefficiencies during its manufacturing footprint transition.

Looking ahead, EPL has raised its revenue growth outlook to high-teen growth, supported by momentum in Beauty and Cosmetics and other segments. Investments are being made ahead of anticipated returns, including capacity expansions and proposed mergers.

The balance sheet reflects these investments, with increased borrowings, though leverage remains manageable at a debt-to-equity ratio of around 0.34. Inventory days have expanded to 177, a factor management attributes to higher polymer prices and safety stock during supply disruptions.

Returns on capital remain healthy, with ROCE around 18% and ROE near 16%, indicating efficient growth management. The current valuation of approximately 20.8 times earnings is below its five-year average, suggesting the market acknowledges growth potential but remains cautious of European profitability concerns.